Welcome to our dedicated page for ADC Therapeutics SA SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA filed a Form S-8 on August 12, 2025 to register 4,850,000 additional common shares (par value CHF 0.08) for issuance under the ADC Therapeutics SA 2019 Equity Incentive Plan. The filing incorporates by reference prior Form S-8 registrations filed on March 15, 2023 and June 30, 2022 and references periodic reports filed in 2025.
Exhibits listed include amended and restated articles, a Swiss counsel opinion, the consent of PricewaterhouseCoopers SA, the amended plan and a filing fee table.
ADC Therapeutics reported consolidated revenue of $18.8 million for the quarter and $41.9 million for the six months, driven by U.S. product sales of ZYNLONTA and increased license/royalty income. The company recorded a net loss of $56.6 million for the quarter and $95.2 million for the six months, reflecting higher R&D spending and a $13.1 million charge for restructuring and impairments tied to a plan to close the UK facility and reduce global headcount by approximately 30%.
Liquidity was strengthened by a June private placement that generated gross $100.0 million (net $93.1 million), leaving cash and cash equivalents at $264.6 million. Material longer-term obligations include a deferred royalty obligation (fair value ~$312.0 million, carrying balance rolled to $340.4 million in the rollforward) and senior secured term loans with a carrying value of $114.5 million and an effective interest rate of 16.15%. Shareholders' deficit was $(199.2) million at June 30, 2025.
ADC Therapeutics SA reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company filed a Current Report on Form 8-K to attach that press release as Exhibit 99.1, and the filing also includes a Cover Page Interactive Data File as Exhibit 104.
The filing states that the information in Item 2.02 and Exhibit 99.1 is incorporated by reference but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The report is signed on behalf of the company by Jose Carmona, Chief Financial Officer. The 8-K itself does not include the detailed financial tables or results within the body of the filing.